ADZA Adeza Biomedical (MM)

Adeza (NASDAQ: ADZA) today announced it will release financial results for quarter ended March 31, 2006 after market close on Thursday, May 4, 2006. Adeza's management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss those results and answer questions. Individuals interested in participating in the conference call may do so by dialing 888-463-4383 for domestic callers, or 706-634-5615 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors section of the company's Web site at www.adeza.com. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering reservation code 8492565. A webcast replay will be available by visiting the Investors section on the Adeza Web site. About Adeza Adeza designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare, using its proprietary technologies to predict preterm birth and assess infertility. Adeza's principal product is a patented diagnostic test, FullTerm(TM), The Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ(R) System. This product is approved by the U.S. Food and Drug Administration (FDA) for use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity(R) Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility. More information is available at www.adeza.com. Adeza cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Adeza that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Adeza's business including, without limitation, statements about the expansion of the indications for its products. All forward-looking statements are qualified in their entirety by this cautionary statement and Adeza undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.